Aims Zolmitriptan (Zomig, formerly known as 311C90), a selective 5HT 1B/1D agonist is under development as an acute oral treatment for migraine. Despite the use of prophylactic medication, such as propranolol, breakthrough attacks often occur in patients. Consequently we investigated the effects of propranolol on the pharmacokinetics of, and cardiovascular responses to, zolmitriptan. Methods A double-blind, randomized, crossover study of the effects of pre-treatment with propranolol 160 mg daily for 7 days or placebo on the pharmacokinetics and effects on blood pressure of a single 10 mg dose of zolmitriptan in 12 healthy volunteers. Results Propranolol increased mean zolmitriptan C max and AUC by 56% and 37% respectively; mean t 1/2 was prolonged from 3.1 to 4.0 h. Mean C max and AUC of the pharmacologically active N-desmethyl metabolite were reduced by 24% and 11% respectively and the metabolite5parent AUC ratio (AUC m /AUC p ) fell from 0.46 to 0.26. Mean C max and AUC for the inactive indole acetic acid metabolite were both reduced by 13% and AUC m /AUC p from 1.04 to 0.59. A small pressor effect of short duration was observed following zolmitriptan with mean peak rises of 13 and 11 mmHg in systolic and diastolic pressures respectively; propranolol had no effect on the pressor response. Conclusions The results suggest that propranolol inhibits biotransformation of zolmitriptan but with no change in the small pressor response to zolmitriptan. It is therefore unlikely that the pharmacokinetic changes will lead to clinically important changes in pharmacological effects and dosage adjustment of zolmitriptan is not required in patients taking propranolol for migraine prophylaxis.
Introduction been demonstrated in vitro but the rates of reaction have been too slow to characterize individual enzymes.
Zolmitriptan, (311C90, (S)-4[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone), is a selective
Propranolol is a first-line drug for the prophylaxis of frequent migraine attacks, at an average daily dose of 5HT 1B/1D receptor agonist in late stage clinical development for the acute, oral treatment of migraine [1] . Two hours 120-160 mg [6] . However, it is not completely effective, consequently patients taking propranolol may also wish to after oral doses of 2.5 mg or above, headache severity is reduced from moderate or severe to mild or none in take zolmitriptan to treat breakthrough attacks. Therefore, in this study, we investigated the impact of pre-treatment with 65-81% of patients compared with improvement in only 15-34% after placebo [2] . After oral dosing up to 50 mg, propranolol on the pharmacokinetics and effects on blood pressure of a single dose of zolmitriptan in healthy volunteers. zolmitriptan produces transient increases in blood pressure, its plasma concentrations are dose-proportional with peak values at 2-4 h after dosing and elimination half-life is Methods 2.5-3.0 h [3] [4] [5] . It is principally eliminated by metabolism [4] ; three metabolites are detected in man: 183C91 (NSubjects desmethyl) is a 5HT 1B/1D receptor agonist at least twice as potent as zolmitriptan; 1652W92 ( N-oxide) and 2161W92
Fourteen healthy volunteers (8M, 6F, age 20-39 years, (indoleacetic acid) are inactive. The involvement of weight 55-89 kg ) were recruited. All were in good general health, non-smokers, taking no regular medication except the oral contraceptive pill and with no significant past Committee and the King's Healthcare Research Ethics profiles. The area under the plasma concentration-time profile (AUC) was calculated by the linear trapezoidal rule Committee. All volunteers gave written informed consent. and extrapolated to infinity by the addition of C t /l z , where C t was the last measured concentration and l z the terminal Study design phase elimination rate constant obtained by log-linear regression. The elimination half-life, t 1/2 , was calculated as The study was of a randomized, balanced, crossover design and double-blind with respect to propranolol. On the two ln(2)/l z . Apparent clearance, CL/F, and volume of distribution, V z /F, were calculated as Dose/AUC and l z CL/F occasions, which were at least 1 week apart, subjects received either propranolol 160 mg (Inderal-LA, Zeneca respectively. Renal clearance (CL R ) was calculated as Ae/AUC(0, 24 h) where Ae, calculated as the product of Pharmaceuticals, Macclesfield) or an identical placebo once daily for 7 days. A 10 mg dose of zolmitriptan was taken urine volume and concentration, was the amount excreted in urine for 24 h after the zolmitriptan dose and AUC(0, with the last dose of propranolol or placebo. All doses were given under supervision, with 200 ml water. For the first 6 24 h) was determined as AUC-(C t /l z ) e −lz (24-t) . Mean residence time (MRT) for zolmitriptan was calculated using days of each occasion, subjects were dosed on an out-patient basis but they were admitted to the study unit 2 h before statistical moments [7] . For the metabolites, the ratio of metabolite5parent AUC, AUC m /AUC p , was calculated. the doses of zolmitriptan and stayed for 24 h afterwards. Subjects were required to fast and abstain from caffeine overnight, and from alcohol for 24 h, before admission to Statistical methods the unit. Based on data from a previous study [5] it was estimated that 12 subjects would give 80% power to detect
Comparisons of pharmacokinetic parameters, except t max , a 20% change in zolmitriptan AUC and a 7 mmHg change after zolmitriptan and propranolol compared with zolmitripin diastolic blood pressure after zolmitriptan and propranolol tan and placebo were performed using ANOVA. All compared with zolmitriptan and placebo, using 2-sided, 5%
parameters, except Ae, were log-transformed prior to level tests.
analysis. The geometric mean ratio and its 95% confidence Blood samples for assay of zolmitriptan and its metabolites interval (CI) were determined for each comparison. For were taken pre-dose on each occasion and 0.25, 0.5, 0.75, t max , differences between median values, and their 95% CIs, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 9, 11, 13, 15 and 24 h after were estimated using the Wilcoxon Rank Sum test in the each dose of zolmitriptan and all urine was collected for manner suggested for taking account of any occasion effect 24 h. Pulse, and blood pressure were recorded before each [8] . Baseline blood pressure was taken as the mean of the dose of propranolol/placebo. Blood pressure was also two measurements recorded 30 and 5 min before zolmitriprecorded 30 and 5 min before zolmitriptan and 0.5, 1, 1.5, tan. Baseline values and the peak post-zolmitriptan increases 2, 2.5, 3, 4, 6, 9, 13 and 24 h afterwards. For all in blood pressures were compared between the propranolol measurements until 4 h post-zolmitriptan subjects were on and placebo occasions by ANOVA and the 95% CIs strict bed rest; subsequent measurements were after at least calculated for the differences between occasions. 10 min resting supine. Twelve-lead ECGs were recorded before and after zolmitriptan and a 2-lead ECG was recorded by Holter tape throughout each subject's days in the unit.
Results
Twelve subjects entered the study initially; one withdrew Drug assay and pharmacokinetic methods due to poor tolerance of the intravenous cannula and another withdrew after a brief, entirely asymptomatic, Plasma was separated and the volume of each urine collection was determined and a 20 ml aliquot taken. Samples were episode of non-sustained ventricular tachycardia, 4 h after dosing, was detected on review of his Holter tape from the stored at −20°C or below. Plasma and urine concentrations of zolmitriptan and metabolites were determined by h.p.l.c. first occasion (zolmitriptan and propranolol). The rest of the tape was unremarkable as were his pre-and post-dose [5]. The calibration range was 2-200 ng ml −1 for all analytes in plasma and 100-2000 ng ml −1 in urine. Pharmacokinetic 12-lead ECGs. The background incidence of non-sustained ventricular tachycardia is 1-2% in healthy subjects [9] and analyses were performed using SIPHAR 4.0b (Simed, 9-11 rue G. Enesco, Crêteil, France). The observed peak plasma the event was not considered drug-related. The comparisons of blood pressure and pharmacokinetic data are from the 12 concentration, C max , and the time to reach the peak concentration, t max , were taken directly from the plasma subjects completing both occasions but adverse experiences are reported from all 14 subjects. The randomization code no net change in AUC [ref 7, page 191] . Thus, although propranolol reduces hepatic blood flow in healthy subjects was not broken until the study had been completed.
Adverse events were all mild or moderate in intensity and [10] this cannot explain its effects on zolmitriptan pharmacokinetics. none was serious. Eleven of the twelve subjects reported adverse events on the placebo treatment arm and ten of Propranolol inhibits CYP2D6 [11] CYP3A4 [12] and CYP1A2 [13] . In addition, it is a substrate for CYP2D6, fourteen reported them on the propranolol arm. Most occurred after the dose of zolmitriptan with the most CYP1A2 and probably also CYP2C19 [14] suggesting the additional possibility of competitive effects for this isozyme. common events being headache, probably related to caffeine restriction, and symptoms of tightness, pressure or discomfort It is not clear which of these actions are responsible for the effects seen in this study. The formation of 183C91, an Nin the face, neck, throat or jaw, typical of this drug class.
Blood pressure and pulse both fell during propranolol desmethyl metabolite is probably mediated by cytochrome P450. However, similarly to sumatriptan [15] the indoledosing. After 7 days propranolol, the mean systolic blood pressure was 3 mmHg lower than after placebo (95% CI−2, acetic acid, 2161W92, is most likely formed by the action of monoamine oxidase (MAO). Although a substrate for 9) and diastolic pressure was 7 mmHg lower (95% CI 4, 10) ( Table 1 ). There was a transient increase in blood pressure MAO [16] , there is no evidence that propranolol is an MAO inhibitor thus the parallel change in 183C91 and after zolmitriptan on both occasions with no differences between zolmitriptan and propranolol compared with 2161W92 concentrations in this study suggests that 2161W92 may be formed by further metabolism of 183C91. zolmitriptan and placebo (Table 1 ). The post dose changes in heart rate were also similar on the two occasions.
Since the higher zolmitriptan concentrations in the presence of propranolol were not associated with a greater In the presence of propranolol, there were 56% and 37% increases in mean zolmitriptan C max and AUC respectively rise in blood pressure, it is likely the potential affects of the increase in zolmitriptan concentrations were offset by the and 24% and 11% falls in mean 183C91 C max and AUC respectively (Table 2 ). 2161W92 C max and AUC were both reduction in concentrations of 183C91 which is also a 5HT 1B/1D receptor agonist or by the blood pressure lowering 13% lower. Mean zolmitriptan half-life increased from 3.1 to 4.0 h and that of 183C91 increased from 3.0 to 4.5 h.
effects of propranolol itself.
In conclusion, propranolol was associated with a reduction Urinary recovery of unchanged drug increased from 15.6% to 22.2% of the administered dose, with a corresponding in the extent of conversion of zolmitriptan to the active metabolite 183C91. However, there were no changes in the decrease in recovery of 2161W92 from 31.2% to 26.4%. Plasma 1652W92 concentrations were low and generally it pharmacological effects on blood pressure and it is unlikely that the pharmacokinetic changes will lead to clinically was not possible to characterize the elimination phase (Table 2 ). There was no obvious effect of propranolol on important changes in therapeutic effect. Consequently dosage adjustment of zolmitriptan is not required in patients taking 1652W92 concentrations.
propranolol for migraine prophylaxis.
Discussion
We acknowledge the skilful bioanalytical assistance of John Allanson. The principle effect of propranolol was to increase plasma zolmitriptan concentrations with a corresponding decrease in the concentrations of metabolites 183C91 and 2161W92.
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